Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29HL046198-05
Application #
2222723
Study Section
Human Embryology and Development Subcommittee 1 (HED)
Project Start
1991-09-01
Project End
1997-08-31
Budget Start
1995-09-01
Budget End
1997-08-31
Support Year
5
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Catlin, E A; Tonnu, V C; Ebb, R G et al. (1997) Mullerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung. Endocrinology 138:790-6
Maggard, M A; Catlin, E A; Hudson, P L et al. (1996) Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive. Metabolism 45:190-5
Catlin, E A; MacLaughlin, D T; Donahoe, P K (1993) Mullerian inhibiting substance: new perspectives and future directions. Microsc Res Tech 25:121-33
Catlin, E A; Ezzell, R M; Donahoe, P K et al. (1993) Identification of a receptor for human mullerian inhibiting substance. Endocrinology 133:3007-13
MacLaughlin, D T; Levin, R K; Catlin, E A et al. (1992) Identification of mullerian inhibiting substance specific binding in human cell lines. Horm Metab Res 24:570-5
Catlin, E A; Ezzell, R M; Donahoe, P K et al. (1992) Mullerian inhibiting substance binding and uptake. Dev Dyn 193:295-9